Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2022 year-end corporate update.
Fourth Quarter Highlights
Over 690 procedures were performed globally during the quarter, representing growth of over 23% compared to the fourth quarter 2021
Five Senhance® Surgical Programs were initiated during the quarter, including two in Germany, two in Japan, and one in the CIS region
Fourth quarter unaudited revenue is expected to be approximately $2.2 - $2.8 million
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.